Table of Contents
Metal-Based Drugs
Volume 2008, Article ID 576104, 6 pages
http://dx.doi.org/10.1155/2008/576104
Review Article

Nuclear Factor-kappa B as a Resistance Factor to Platinum-Based Antineoplasic Drugs

1Laboratorio de Biología Molecular, Subdirección de Investigación Básica, Instituto Nacional de Cancerológica, Avenida San Fernando 22, Tlalpan 14080, Mexico
2Genómica Funcional de Cáncer de Laboratorio, Instituto Nacional de Medicina Genomita, Mexico City 03020, Mexico

Received 12 July 2007; Accepted 18 December 2007

Academic Editor: Rafael Moreno-Sanchez

Copyright © 2008 Vilma Maldonado Lagunas and Jorge Meléndez-Zajgla. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [8 citations]

The following is the list of published articles that have cited the current article.

  • Catherine E. Wharry, and Michael J. May, “Raising the price of platinum: Inhibition of NFκB in human tumor epithelial cells,” Cancer Biology and Therapy, vol. 7, no. 9, pp. 1415–1417, 2008. View at Publisher · View at Google Scholar
  • Man Jiang, and Zheng Dong, “Regulation and pathological role of p53 in cisplatin nephrotoxicity,” Journal of Pharmacology and Experimental Therapeutics, vol. 327, no. 2, pp. 300–307, 2008. View at Publisher · View at Google Scholar
  • Maria Chiara Zatelli, Daniela Molè, Federico Tagliati, Mariella Minoia, Maria Rosaria Ambrosio, and Ettore Degli Uberti, “Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF-κB,” Cellular Oncology, vol. 31, no. 6, pp. 457–465, 2009. View at Publisher · View at Google Scholar
  • Tanvi S. Jani, Jennifer DeVecchio, Tapati Mazumdar, Akwasi Agyeman, and Janet A. Houghton, “Inhibition of NF-κB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or Oxaliplatin,” Journal of Biological Chemistry, vol. 285, no. 25, pp. 19162–19172, 2010. View at Publisher · View at Google Scholar
  • E Tsvetkova, and G D Goss, “Drug resistance and its significance for treatment decisions in non-small-cell lung cancer.,” Current oncology (Toronto, Ont.), vol. 19, no. Suppl1, 2012. View at Publisher · View at Google Scholar
  • J Kumar, F W Fraser, C Riley, N Ahmed, D R McCulloch, and A C Ward, “Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer,” British Journal of Cancer, 2013. View at Publisher · View at Google Scholar
  • Anil Kumar, Shuaidong Huo, Xu Zhang, Juan Liu, Aaron Tan, Shengliang Li, Shubin Jin, Xiangdong Xue, YuanYuan Zhao, Tianjiao Ji, Lu Han, Hong Liu, XiaoNing Zhang, Jinchao Zhang, Guozhang Zou, Tianyou Wang, Suoqin Tang, and Xing-Jie Liang, “Neuropilin-1-Targeted Gold Nanoparticles Enhance Therapeutic Efficacy of Platinum(IV) Drug for Prostate Cancer Treatment,” ACS Nano, pp. 140414145126005, 2014. View at Publisher · View at Google Scholar
  • Teodora Nikolova, Nicole Kiweler, and Oliver H. Krämer, “Interstrand Crosslink Repair as a Target for HDAC Inhibition,” Trends in Pharmacological Sciences, 2017. View at Publisher · View at Google Scholar